The substance patent of the DDP-4 diabetes treatment ‘Januvia’ has been the main target
Chong Kun Dang, Jeil Pharmaceutical and Hanmi Pharm have recently filed a nullity trial for the substance patent of Januvia.
As working on approval procedures, these pharmaceutical companies will be the first ones launching generics of Januvia in the world if the nullity trial is accepted.
Acco...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
